EHA 2026: MRD Predicts Post-Transplant Relapse in High-Risk MDS and AML

In this MEDtalk from the EHA 2026 Congress, Caroline Arvé, Medical Student, Department of Hematology, Aarhus University Hospital, Denmark, presents results from a Danish study evaluating patient-specific digital PCR-based measurable residual disease (MRD) assessment before transplantation in high-risk MDS and myelodysplasia-related AML. She discusses how molecular MRD positivity predicted post-transplant relapse and how combining molecular and flow cytometry MRD further improved prognostic stratification.